Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price Target
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $20 price target.
Read original at benzingaStocks · News reference
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 10:04 AM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Climb Bio shares are trading higher after Beijing Mabworks Biotech announced the dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy in China, conducted in collaboration with Climb Bio.
Read original at benzinga8-K filing — Climb Bio, Inc. (CLYM)
Filed: 2026-08-14 AccNo: 0001193125-26-350596 Size: 141 KB Item 8.01: Other Events
Read original at edgar